DE3586402D1 - Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung. - Google Patents

Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung.

Info

Publication number
DE3586402D1
DE3586402D1 DE8585100223T DE3586402T DE3586402D1 DE 3586402 D1 DE3586402 D1 DE 3586402D1 DE 8585100223 T DE8585100223 T DE 8585100223T DE 3586402 T DE3586402 T DE 3586402T DE 3586402 D1 DE3586402 D1 DE 3586402D1
Authority
DE
Germany
Prior art keywords
protein
factor viiic
compsn
polypeptide
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585100223T
Other languages
English (en)
Other versions
DE3586402T2 (de
DE3586402T3 (de
Inventor
George Kuo
Frank R Masiarz
Martha Truett
Pablo Valenzuela
Mirella Ezban Rasmussen
Jennifer Favaloro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordisk Gentofte AS
Novartis Vaccines and Diagnostics Inc
Original Assignee
Nordisk Gentofte AS
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27075219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3586402(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/570,062 external-priority patent/US5004804A/en
Application filed by Nordisk Gentofte AS, Chiron Corp filed Critical Nordisk Gentofte AS
Publication of DE3586402D1 publication Critical patent/DE3586402D1/de
Publication of DE3586402T2 publication Critical patent/DE3586402T2/de
Application granted granted Critical
Publication of DE3586402T3 publication Critical patent/DE3586402T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3586402T 1984-01-12 1985-01-11 Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung. Expired - Lifetime DE3586402T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US570062 1984-01-12
US06/570,062 US5004804A (en) 1984-01-12 1984-01-12 Method and composition for preparation of factor VIIIC
US66491984A 1984-10-26 1984-10-26
US664919 1984-10-26

Publications (3)

Publication Number Publication Date
DE3586402D1 true DE3586402D1 (de) 1992-09-03
DE3586402T2 DE3586402T2 (de) 1993-01-07
DE3586402T3 DE3586402T3 (de) 2004-12-23

Family

ID=27075219

Family Applications (6)

Application Number Title Priority Date Filing Date
DE3586402T Expired - Lifetime DE3586402T3 (de) 1984-01-12 1985-01-11 Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung.
DE2003199011 Pending DE10399011I1 (de) 1984-01-12 1985-01-11 F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
DE2003199009 Pending DE10399009I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
DE2003199010 Pending DE10399010I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
DE200412000028 Pending DE122004000028I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen.
DE3588242T Expired - Lifetime DE3588242T2 (de) 1984-01-12 1985-01-11 Für Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen

Family Applications After (5)

Application Number Title Priority Date Filing Date
DE2003199011 Pending DE10399011I1 (de) 1984-01-12 1985-01-11 F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
DE2003199009 Pending DE10399009I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
DE2003199010 Pending DE10399010I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
DE200412000028 Pending DE122004000028I1 (de) 1984-01-12 1985-01-11 F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen.
DE3588242T Expired - Lifetime DE3588242T2 (de) 1984-01-12 1985-01-11 Für Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen

Country Status (7)

Country Link
EP (3) EP0150735B2 (de)
JP (5) JPH0826078B2 (de)
AT (2) ATE224445T1 (de)
DE (6) DE3586402T3 (de)
DK (3) DK165506C (de)
LU (4) LU91014I2 (de)
NL (4) NL300118I2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲viii▼および関連生産物の製造
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
EP0182448A3 (de) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (de) * 1985-04-12 1992-02-26 Genetics Institute, Inc. Neue prokoagulierungsproteine
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
EP0272304B1 (de) * 1986-06-24 1994-01-26 Novo Nordisk A/S Verfahren zur herstellung eines koagulationsaktiven komplexes vom faktor viii-fragment
ATE63335T1 (de) 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
WO1988005825A1 (en) * 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
EP0294910B1 (de) 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
CA2067158A1 (en) * 1989-09-14 1991-03-15 R. Alan Hardwick Method and useful apparatus for preparing pharmaceutical compositions
US5610033A (en) * 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US6500646B1 (en) * 1996-12-27 2002-12-31 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第viii因子処方物
EP1418810A4 (de) 2001-08-03 2006-08-02 Us Gov Health & Human Serv Orale behandlung von hämophilie
AU2003269557A1 (en) * 2002-10-18 2004-05-04 Lg Life Sciences Ltd. Gene families associated with cancers
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
IE80858B1 (en) * 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4663280A (en) * 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲viii▼および関連生産物の製造
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPH0634760A (ja) * 1992-07-15 1994-02-10 Hamamatsu Photonics Kk 放射線計測装置及び核医学診断装置

Also Published As

Publication number Publication date
EP0150735B2 (de) 2004-01-07
JP2002186487A (ja) 2002-07-02
LU91015I2 (fr) 2003-06-19
DK165506C (da) 1993-04-19
DE10399011I1 (de) 2003-10-23
EP0150735A2 (de) 1985-08-07
DK13585D0 (da) 1985-01-11
EP0466199A1 (de) 1992-01-15
LU91087I2 (fr) 2004-08-26
ATE224445T1 (de) 2002-10-15
DE10399009I1 (de) 2003-10-23
DK38892D0 (da) 1992-03-25
NL300153I1 (nl) 2004-09-01
DE10399010I1 (de) 2003-10-23
EP1006182A3 (de) 2000-06-14
NL300119I1 (nl) 2003-06-02
DE3588242D1 (de) 2002-10-31
NL300118I1 (nl) 2003-06-02
EP0150735B1 (de) 1992-07-29
EP1006182A2 (de) 2000-06-07
JPH0826078B2 (ja) 1996-03-13
JPH06105688A (ja) 1994-04-19
NL300120I1 (nl) 2003-06-02
NL300118I2 (nl) 2004-06-01
DK13585A (da) 1985-09-11
JPH04218399A (ja) 1992-08-07
DK169708B1 (da) 1995-01-16
ATE78871T1 (de) 1992-08-15
LU91014I2 (fr) 2003-06-19
JP2000023670A (ja) 2000-01-25
DK150992A (da) 1992-12-17
JPH0634760B2 (ja) 1994-05-11
LU91013I2 (fr) 2003-06-19
DK38892A (da) 1992-03-25
DE3586402T2 (de) 1993-01-07
DK165506B (da) 1992-12-07
DK169724B1 (da) 1995-01-23
EP0466199B1 (de) 2002-09-18
EP0150735A3 (en) 1987-07-01
JPS60185723A (ja) 1985-09-21
DE122004000028I1 (de) 2004-09-30
DE3588242T2 (de) 2004-03-11
DE3586402T3 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
DE3586402D1 (de) Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung.
ATE90792T1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ATE197155T1 (de) Stannius- körperchen -protein, stanniocalcin
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE69233155D1 (de) Insulinartigen wachstumsfaktor bindendes protein
DE58901435D1 (de) Verfahren zur herstellung von dipeptiden mit n-terminalen nichtproteinogenen aminosaeuren.
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
ATE115188T1 (de) Antikörper gegen fibrin, immunogen zur herstellung desselben, verfahren zur bestimmung von fibrin und pharmazeutisches präparat auf basis der antikörper.
ATE94905T1 (de) Verfahren zur herstellung von fremdproteinen in streptomyceten.
Sanger Les Prix Nobel en 1958
KR950018049A (ko) 사람 dna 토포이소머라제 제i형의 돌연변이체 단백질
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.
ATE102950T1 (de) Verfahren zur herstellung von dipeptiden mit cterminalen nicht-proteinogenen aminosaeuren.
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings